Valence 로고
인기
로그인
Loading data for INDV — first visit, this takes a few seconds.

관심목록에 추가

Indivior Pharmaceuticals ...

NasdaqGS: INDV · 실시간 가격 · USD
39.43
+0.35 (0.90%)
종가 기준: Aug 19, 2026, 1:46 PM

Indivior Pharmaceuticals Inc. (INDV) Stock Price, Analysis & Data

0.90%

데이터 없음

매수호가28.41
시가총액4.7B
매출 (ttm)1.33B
순이익 (ttm)356M
베타1.14
EPS (ttm)2.79
P/E (ttm)14.28
선행 P/E8.16
P/B (ttm)-22.60
P/S (ttm)3.53
Earnings DateNov 5, 2026
매도호가50.7
거래량1,495,481
평균 거래량 (20일)2,008,249
시가39.48
전일 종가39.08
일중 범위39.08 - 39.90
52주 범위22.22 - 42.81
애널리스트n/a
목표주가n/a
배당n/a
배당락일2016년 6월 16일

INDV 소개

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; a...

[더 보기]
산업 Drug Manufacturers - Specialty & Generic
섹터 Healthcare
IPO 일자 Dec 29, 2014
직원 수 827
상장 거래소 NasdaqGS
티커 INDV
웹사이트 https://www.indivior.com
전체 기업 정보

재무 실적

2025년 Indivior Pharmaceuticals의 매출은 1.24B로, 전년 1.19B 대비 4.29% 증가했습니다. 순이익은 210M로, 2,900% 증가했습니다.

재무제표

어닝 서프라이즈

Indivior Pharmaceuticals가 Aug 3, 2026에 분기 실적을 발표했습니다:
  • 매출 $343M 예상치 하회 $0, 및 13.58% 전년 대비 성장.
  • EPS 1.15 예상치 상회 0.23, 및 125.49% 전년 대비 성장.

    • 다음 실적 발표

    Indivior Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1주 전 · Zacks

    Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"

    Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.

    news image

    2주 전 · Zacks

    INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

    Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

    news image

    2주 전 · MarketBeat

    Indivior Q2 Earnings Call Highlights

    Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharm...

    news image

    2주 전 · Investing.com

    Supernus jumps premarket on merger deal; GameStop drops

    Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets ...

    news image

    2주 전 · Zacks

    Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates

    Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +18.56% and +11.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for th...

    2 페이지 중 1